Truist raises Callaway Golf stock price target on self-help factors

Truist Securities raised its price target for Callaway Golf (NYSE:ELY) to $20.00 from $19.00, citing self-help factors like SKU rationalization and store closures. The stock is up 64% over the past year. Callaway reported Q2 2026 earnings of $0.39 per share, beating estimates, with revenue of $612.2 million and a 36% increase in adjusted EBITDA.

Original reporting
Published Sep 1, 2026, 3:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$CALY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could trigger short‑term buying pressure, but investors should monitor upcoming earnings for confirmation.

02

Market read

Analyst upgrade adds modest upside potential for Callaway Golf and may influence sector sentiment.

03

What to watch

Potential headwinds from discretionary spending slowdown and competition from lower‑priced brands.

Relevance 7/10Novelty 7/10Timing: Monday (report date)

Background

Truist highlighted lower‑margin SKU rationalization, store closures, and stock repurchases as catalysts.

Market effects

Positive signal for the golf equipment sector as margin improvements may be echoed by peers.

U.S. consumer discretionary stocks could see modest uplift.

Limited to markets tracking U.S. consumer discretionary equities.

Counterpoint

The price target raise may be premature if margin gains are not sustainable.

Key entities

  • Truist Securities

    Equity research firm that issued the price target raise.

  • Callaway Golf

    Manufacturer of golf equipment, ticker ELY.

Related articles

$CALYMed

A golf brand reclaimed the No. 1 U.S. golf club spot from 2015 to 2020. Callaway's former brand chief is back.

Callaway Golf Company (NYSE: CALY) appointed Harry Arnett as Senior Vice President and Chief Brand Officer. Arnett previously led Callaway's brand strategy and will now focus on global brand strategy and demand creation. According to CEO Chip Brewer, Arnett's return aims to strengthen Callaway's connection with golfers and drive market-share growth.

$CALYMed

CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS

Callaway Golf Co (CALY) filed an SEC Form 8-K — Results of Operations and Financial Condition. CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS Second Quarter Net Sales (+2%), GAAP Net Income from Continuing Operations (+67%) and Adjusted EBITDA (+36%) Raises Full-Year Guidance HIGHLIGHTS • Q2 GAAP and Non-GAAP Gross Margin increased 620 basis points and 460 bas

$MESOMed

Operating cash spending at Mesoblast fell 86% from a year earlier to US$2.1 million.

Mesoblast reported an 86% drop in operating cash spending to $2.1M. Sales of Ryoncil® grew, and trials for rexlemestrocel-L in chronic pain and cardiovascular diseases advanced. FDA confirmed a BLA filing for rexlemestrocel-L in end-stage heart failure. The company met with FDA to discuss treatment for life-threatening gastrointestinal bleeding. Mesoblast is listed on Nasdaq (MESO) and ASX (MSB).

$CHRSMedAI 8/10

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Coherus Oncology (NASDAQ:CHRS) reported interim results from an early study of its drug in esophageal squamous cell carcinoma (ESCC), showing a 33.3% clinical benefit rate at a 700 mg dose. The company plans to meet with the FDA to discuss the go-forward dose and potential accelerated approval strategies. Coherus also shared interim findings for head and neck cancer, upper gastrointestinal adenocarcinomas, and colorectal cancer.